Class IIITerminatedD-0926-2017
Drug recall · July 5, 2017
Gaviscon recall
Why: Superpotent Drug: high out-of-specification result for magnesium.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distributed by: GlaxoSmithKline Consumer Healthcare, L.P., Moon Twp, PA 15108, UPC 3 0088-1175-47 8.
- Lots / codes
Lot #: 5J69A, Exp 02/19; 6GF2A, 6GF3A, Exp 08/19
- Quantity
- 2980 bottles
- Company
- Sanofi-Aventis U.S. LLC, Bridgewater, NJ
- Distribution
- Nationwide in the USA, Puerto Rico, and the United Kingdom.
- Initiated
- June 12, 2017 · Voluntary: Firm initiated
- Classified
- June 29, 2017
- Reported
- July 5, 2017
- Ended
- February 7, 2019
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.